Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
Altace Plus Felodipine | Ramipril/felodipine extended release | Hypertension | Do not list | Complete | ||
Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
VFEND | Voriconazole | Candidemia | List with clinical criteria and/or conditions | Complete | ||
Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Enablex | Darifenacin hydrobromide | Bladder, overactive | Do not list | Complete | ||
Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
Fosavance | Alendronate sodium/cholecalciferol | Osteoporosis | Do not list | Complete | ||
Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | List with clinical criteria and/or conditions | Complete | ||
DuoTrav | Travoprost and timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | ||
Trosec | Trospium chloride | Bladder, overactive | List with clinical criteria and/or conditions | Complete |